FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2999168510> ?p ?o ?g. }

• W2999168510 endingPage "xi20" @default.
• W2999168510 startingPage "xi20" @default.
• W2999168510 abstract "ABSTRACT Background Gastric cancer is a frequent malignancy with worldwide estimated incidence of 990'000 cases, representing 7.8% of all cancers in 2008. There are limited data suggesting a benefit for doublet second-line chemotherapy in advanced gastric cancer. Methods The eligibility criteria were patients 1) with prior exposure to cisplatin based chemotherapy and advanced or recurrent stomach cancer 2) with pathologically proven gastric adenocarcinoma, 3) with an ECOG performance status 0 to 2, 4) with measurable lesions. Each treatment cycle was consisted of docetaxel 36 mg/m2 in docetaxel mono therapy group and docetaxel 36 mg/m2, oxaliplatin 80 mg/m2 in docetaxel/oxaliplatin doublet therapy group on days 1, 8. The primary end point of this study was response rate, and secondary end points included toxicity, progression free and overall survival. Results Fifty two patients were enrolled; median age was 63 years; male (n = 42) and female (n = 10); docetaxel mono therapy (n = 27) and docetaxel/oxalliplatin doublet therapy (n = 25). The median number of cycles administered was 2.5 (range,1-9). Fourty eight patients were assessable for efficacy. Four partial responses, 7 stable diseases in mono therapy group (RR; 4/27, 14.8%) and 1 complete remission, 4 partial responses, 13 stable diseases in double therapy group (RR; 5/25, 20.0%) were confirmed (P = 0.198). Median progression free survival was 1.97 months in the mono therapy group and 4.93 months in doublet therapy group (P = 0.007). Median overall survival was 11.57 months in the mono therapy group and 8.13 months in doublet therapy group (P = 0.650). Grade 3 or 4 adverse events were reported in 11 of 52 patients; G3 pain were in 2 patients and G3 pneumonia was in 1 patient in mono group, G3/4 neutropenia were 5 patients in the combination group, G3 nausea, vomiting, general weakness was 1 patient each group in combination group. Conclusions Weekly docetaxel/oxaliplatin doublet therapy showed superior progression free survival to monotherapy group as second line therapy in cisplatin pretreated advanced gastric cancer patients." @default.
• W2999168510 created "2020-01-23" @default.
• W2999168510 creator A5001672070 @default.
• W2999168510 creator A5031029882 @default.
• W2999168510 creator A5033153926 @default.
• W2999168510 creator A5038406346 @default.
• W2999168510 creator A5056474010 @default.
• W2999168510 creator A5059915781 @default.
• W2999168510 creator A5064477487 @default.
• W2999168510 creator A5072759397 @default.
• W2999168510 creator A5081447935 @default.
• W2999168510 creator A5090060625 @default.
• W2999168510 creator A5090274131 @default.
• W2999168510 date "2012-10-01" @default.
• W2999168510 modified "2023-09-29" @default.
• W2999168510 title "Multicenter Randomized Phase II Study of Weekly Docetaxel Alone Versus Weekly Docetaxel Plus Oxaliplatin as a Second-Line Chemotherapy in Patients with Advanced Gastric Cancer: Preliminary Response and Safety Results" @default.
• W2999168510 doi "https://doi.org/10.1016/s0923-7534(20)31969-4" @default.
• W2999168510 hasPublicationYear "2012" @default.
• W2999168510 type Work @default.
• W2999168510 sameAs 2999168510 @default.
• W2999168510 citedByCount "0" @default.
• W2999168510 crossrefType "journal-article" @default.
• W2999168510 hasAuthorship W2999168510A5001672070 @default.
• W2999168510 hasAuthorship W2999168510A5031029882 @default.
• W2999168510 hasAuthorship W2999168510A5033153926 @default.
• W2999168510 hasAuthorship W2999168510A5038406346 @default.
• W2999168510 hasAuthorship W2999168510A5056474010 @default.
• W2999168510 hasAuthorship W2999168510A5059915781 @default.
• W2999168510 hasAuthorship W2999168510A5064477487 @default.
• W2999168510 hasAuthorship W2999168510A5072759397 @default.
• W2999168510 hasAuthorship W2999168510A5081447935 @default.
• W2999168510 hasAuthorship W2999168510A5090060625 @default.
• W2999168510 hasAuthorship W2999168510A5090274131 @default.
• W2999168510 hasBestOaLocation W29991685101 @default.
• W2999168510 hasConcept C121608353 @default.
• W2999168510 hasConcept C126322002 @default.
• W2999168510 hasConcept C143998085 @default.
• W2999168510 hasConcept C2776694085 @default.
• W2999168510 hasConcept C2778336483 @default.
• W2999168510 hasConcept C2780962732 @default.
• W2999168510 hasConcept C2781190966 @default.
• W2999168510 hasConcept C31760486 @default.
• W2999168510 hasConcept C526805850 @default.
• W2999168510 hasConcept C71924100 @default.
• W2999168510 hasConceptScore W2999168510C121608353 @default.
• W2999168510 hasConceptScore W2999168510C126322002 @default.
• W2999168510 hasConceptScore W2999168510C143998085 @default.
• W2999168510 hasConceptScore W2999168510C2776694085 @default.
• W2999168510 hasConceptScore W2999168510C2778336483 @default.
• W2999168510 hasConceptScore W2999168510C2780962732 @default.
• W2999168510 hasConceptScore W2999168510C2781190966 @default.
• W2999168510 hasConceptScore W2999168510C31760486 @default.
• W2999168510 hasConceptScore W2999168510C526805850 @default.
• W2999168510 hasConceptScore W2999168510C71924100 @default.
• W2999168510 hasLocation W29991685101 @default.
• W2999168510 hasOpenAccess W2999168510 @default.
• W2999168510 hasPrimaryLocation W29991685101 @default.
• W2999168510 hasRelatedWork W1507921223 @default.
• W2999168510 hasRelatedWork W1969868300 @default.
• W2999168510 hasRelatedWork W1976599095 @default.
• W2999168510 hasRelatedWork W1991898793 @default.
• W2999168510 hasRelatedWork W2049497600 @default.
• W2999168510 hasRelatedWork W2116776417 @default.
• W2999168510 hasRelatedWork W2283573400 @default.
• W2999168510 hasRelatedWork W2691828966 @default.
• W2999168510 hasRelatedWork W3010009488 @default.
• W2999168510 hasRelatedWork W3089122812 @default.
• W2999168510 hasVolume "23" @default.
• W2999168510 isParatext "false" @default.
• W2999168510 isRetracted "false" @default.
• W2999168510 magId "2999168510" @default.
• W2999168510 workType "article" @default.